Mesenteric ischemia is a surgical emergency caused by a transient reduction in blood perfusion to the bowel. Despite accounting for only 0.1% of hospital admissions and 1–2% of gastrointestinal diseases, its elusive symptoms often lead to dramatically high morbidity and mortality rates. The complex cascade of inflammatory events and mediators triggered by mesenteric ischemia-reperfusion (I/R) accounts for the plethora of proposed pharmacological targets and for the current lack of an efficacious drug strategy for its management. It is hoped that a deeper understanding of its pathogenesis and the preclinical therapeutic strategies identified to date and described herein will improve the translation into the clinical setting of the pharmacological armamentarium against a life-threatening disorder that is currently mainly managed surgically.

肠系膜缺血是外科手术中的紧急情况，由肠内血液灌注的短暂减少引起。尽管仅占住院人数的0.1％和胃肠道疾病的1-2％，但其难以捉摸的症状通常会导致发病率和死亡率急剧上升。由肠系膜缺血-再灌注（I / R）触发的炎症事件和介体的复杂级联是提出的许多药理学靶标的原因，也是目前缺乏有效的药物治疗策略的原因。希望更深入地了解其发病机理和迄今鉴定并在本文中描述的临床前治疗策略将改善针对目前主要通过外科手术治疗的威胁生命的疾病的药房的临床应用。